Goldman Sachs Group Inc Taysha Gene Therapies, Inc. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,058,962 shares of TSHA stock, worth $3.63 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,058,962
Previous 83,474
1168.61%
Holding current value
$3.63 Million
Previous $147,000
1967.35%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding TSHA
# of Institutions
111Shares Held
109MCall Options Held
108KPut Options Held
158K-
Avoro Capital Advisors LLC New York, NY18.7MShares$64 Million0.65% of portfolio
-
Rtw Investments, LP New York, NY18.6MShares$63.8 Million0.86% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$30.9 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$20.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY5.17MShares$17.7 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $166M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...